CY1110753T1 - Αναστολεις της 11-βητα-υδροξυστεροειδους αφυδρογονασης i - Google Patents

Αναστολεις της 11-βητα-υδροξυστεροειδους αφυδρογονασης i

Info

Publication number
CY1110753T1
CY1110753T1 CY20101100792T CY101100792T CY1110753T1 CY 1110753 T1 CY1110753 T1 CY 1110753T1 CY 20101100792 T CY20101100792 T CY 20101100792T CY 101100792 T CY101100792 T CY 101100792T CY 1110753 T1 CY1110753 T1 CY 1110753T1
Authority
CY
Cyprus
Prior art keywords
compounds
inhibitions
beta
type
formula
Prior art date
Application number
CY20101100792T
Other languages
English (en)
Inventor
Julie Kay Bush
Marvin Martin Hansen
Renhua Li
Thomas Edward Mabry
Nancy June Snyder
Owen Brendan Wallace
Yanping Xu
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38564359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1110753(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1110753T1 publication Critical patent/CY1110753T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/50—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Η παρούσα εφεύρεση αποκαλύπτει νέες ενώσεις του Τύπου (I) οι οποίες διαθέτουν ανταγωνιστική δραστικότητα έναντι της 11-HSD τύπου I, καθώς επίσης και μεθόδους παρασκευής των ενώσεων του είδους αυτού. Σε μια άλλη ενσωμάτωση, η εφεύρεση αποκαλύπτει φαρμακευτικές συνθέσεις που περιέχουν τις ενώσεις του Τύπου I, όπως επίσης και μεθόδους χρήσης των ενώσεων και των συνθέσεων στην αγωγή διαβήτη, υπεργλυκαιμίας, παχυσαρκίας, υπέρτασης, υπερλιπιδαιμίας, μεταβολικού συνδρόμου και άλλων καταστάσεων που συνδέονται με την δραστικότητα της 11-HSD τύπου I.
CY20101100792T 2006-04-24 2010-08-30 Αναστολεις της 11-βητα-υδροξυστεροειδους αφυδρογονασης i CY1110753T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74547506P 2006-04-24 2006-04-24
EP07761091A EP2021336B1 (en) 2006-04-24 2007-04-23 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

Publications (1)

Publication Number Publication Date
CY1110753T1 true CY1110753T1 (el) 2015-06-10

Family

ID=38564359

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100792T CY1110753T1 (el) 2006-04-24 2010-08-30 Αναστολεις της 11-βητα-υδροξυστεροειδους αφυδρογονασης i

Country Status (33)

Country Link
US (1) US8153807B2 (el)
EP (1) EP2021336B1 (el)
JP (1) JP5269765B2 (el)
KR (1) KR101059614B1 (el)
CN (1) CN101432275B (el)
AT (1) ATE472542T1 (el)
AU (1) AU2007244955B2 (el)
BR (1) BRPI0710467A2 (el)
CA (1) CA2646624C (el)
CO (1) CO6140034A2 (el)
CR (2) CR10402A (el)
CY (1) CY1110753T1 (el)
DE (1) DE602007007473D1 (el)
DK (1) DK2021336T3 (el)
EA (1) EA015106B1 (el)
EC (1) ECSP088833A (el)
ES (1) ES2345792T3 (el)
HK (1) HK1126208A1 (el)
HR (1) HRP20100397T1 (el)
IL (1) IL194810A (el)
MA (1) MA30686B1 (el)
MX (1) MX2008013649A (el)
MY (1) MY148079A (el)
NO (1) NO20084318L (el)
NZ (1) NZ571176A (el)
PL (1) PL2021336T3 (el)
PT (1) PT2021336E (el)
RS (1) RS51450B (el)
SI (1) SI2021336T1 (el)
TN (1) TNSN08417A1 (el)
UA (1) UA94741C2 (el)
WO (1) WO2007127688A2 (el)
ZA (1) ZA200808687B (el)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820659B2 (en) 2006-04-21 2010-10-26 Eli Lilly And Company Cyclohexylimidiazole lactam derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase 1
CN101541747B (zh) 2006-04-21 2012-11-14 伊莱利利公司 作为11-β-羟基甾族化合物脱氢酶1的抑制剂的联苯基酰胺内酰胺衍生物
ES2533263T3 (es) * 2006-04-21 2015-04-08 Eli Lilly And Company Derivados de ciclohexilpirazol-lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
PL2029529T3 (pl) 2006-04-24 2010-11-30 Lilly Co Eli PODSTAWIONE PIROLIDYNONY JAKO INHIBITORY DEHYDROGENAZY 11-ß-HYDROKSYSTEROIDOWEJ TYPU 1
SI2049475T1 (sl) 2006-04-24 2012-04-30 Lilly Co Eli Pirolidinoni substituirani s cikloheksilom kot inhibitorji 11-betahidroksisteroid dehidrogenaze 1
EA016360B1 (ru) 2006-04-25 2012-04-30 Эли Лилли Энд Компани Ингибиторы 11-бета-гидроксистероид дегидрогеназы 1, фармацевтическая композиция на их основе и их применение
WO2007127763A2 (en) 2006-04-25 2007-11-08 Eli Lilly And Company Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
SI2021337T1 (sl) 2006-04-25 2010-05-31 Lilly Co Eli Inhibitorji beta hidroksisteroidne dehidrogenaze
MX2008013844A (es) 2006-04-28 2008-11-10 Lilly Co Eli Pirrolidinonas substituidas con pieridinilo como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1.
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8507493B2 (en) 2009-04-20 2013-08-13 Abbvie Inc. Amide and amidine derivatives and uses thereof
US8871208B2 (en) * 2009-12-04 2014-10-28 Abbvie Inc. 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
CN111356676B (zh) * 2017-12-21 2022-09-27 广东众生睿创生物科技有限公司 作为ppar激动剂的吡咯烷衍生物的无定形及其制备方法
CN110483514B (zh) * 2019-09-16 2022-06-14 启元生物(杭州)有限公司 一种氰基取代的环肼衍生物及其应用
CN110724142B (zh) * 2019-10-29 2022-09-02 启元生物(杭州)有限公司 一种作为jak激酶抑制剂的酰胺或磺酰胺取代的肼衍生物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
CA2565630C (en) * 2004-05-07 2013-05-28 Janssen Pharmaceutica N.V. Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
PL1747198T3 (pl) * 2004-05-07 2008-11-28 Janssen Pharmaceutica Nv Pochodne adamantylopirolidyn-2-onu jako inhibitory 11ß-dehydrogenazy hydroksysteroidowej
US8138342B2 (en) 2004-10-12 2012-03-20 High Point Pharmacueticals, LLC 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds
ATE419848T1 (de) * 2004-10-29 2009-01-15 Lilly Co Eli Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1
GEP20125565B (en) 2004-11-10 2012-07-10 Incyte Corp Lactam compounds and their pharmaceutical use
ATE399546T1 (de) * 2004-12-20 2008-07-15 Lilly Co Eli Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1
ATE401073T1 (de) * 2004-12-21 2008-08-15 Lilly Co Eli Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1
WO2006104280A1 (ja) * 2005-03-31 2006-10-05 Takeda Pharmaceutical Company Limited 糖尿病の予防・治療剤
WO2007066921A1 (en) * 2005-12-08 2007-06-14 Ho Young Lee Structure of sticking extraneous matter and warm foot digital compression plate
WO2007084314A2 (en) 2006-01-12 2007-07-26 Incyte Corporation MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
CN101541747B (zh) 2006-04-21 2012-11-14 伊莱利利公司 作为11-β-羟基甾族化合物脱氢酶1的抑制剂的联苯基酰胺内酰胺衍生物
ES2533263T3 (es) 2006-04-21 2015-04-08 Eli Lilly And Company Derivados de ciclohexilpirazol-lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
US7820659B2 (en) * 2006-04-21 2010-10-26 Eli Lilly And Company Cyclohexylimidiazole lactam derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase 1
PL2029529T3 (pl) * 2006-04-24 2010-11-30 Lilly Co Eli PODSTAWIONE PIROLIDYNONY JAKO INHIBITORY DEHYDROGENAZY 11-ß-HYDROKSYSTEROIDOWEJ TYPU 1
SI2049475T1 (sl) * 2006-04-24 2012-04-30 Lilly Co Eli Pirolidinoni substituirani s cikloheksilom kot inhibitorji 11-betahidroksisteroid dehidrogenaze 1
SI2021337T1 (sl) 2006-04-25 2010-05-31 Lilly Co Eli Inhibitorji beta hidroksisteroidne dehidrogenaze
WO2007127763A2 (en) 2006-04-25 2007-11-08 Eli Lilly And Company Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
EA016360B1 (ru) * 2006-04-25 2012-04-30 Эли Лилли Энд Компани Ингибиторы 11-бета-гидроксистероид дегидрогеназы 1, фармацевтическая композиция на их основе и их применение
MX2008013844A (es) 2006-04-28 2008-11-10 Lilly Co Eli Pirrolidinonas substituidas con pieridinilo como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1.
US20090008890A1 (en) * 2007-06-13 2009-01-08 Woodford James R Suspension system for an all-terrain vehicle
CL2008001839A1 (es) 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
US8871208B2 (en) * 2009-12-04 2014-10-28 Abbvie Inc. 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof

Also Published As

Publication number Publication date
EP2021336B1 (en) 2010-06-30
US20090111809A1 (en) 2009-04-30
ECSP088833A (es) 2008-11-27
CN101432275A (zh) 2009-05-13
DK2021336T3 (da) 2010-09-13
EA200870470A1 (ru) 2009-04-28
MA30686B1 (fr) 2009-09-01
WO2007127688A2 (en) 2007-11-08
PT2021336E (pt) 2010-07-19
AU2007244955A1 (en) 2007-11-08
CN101432275B (zh) 2013-10-30
CR10401A (es) 2009-01-14
NZ571176A (en) 2011-10-28
EA015106B1 (ru) 2011-06-30
ATE472542T1 (de) 2010-07-15
MX2008013649A (es) 2008-11-04
JP5269765B2 (ja) 2013-08-21
CA2646624A1 (en) 2007-11-08
HRP20100397T1 (hr) 2010-09-30
UA94741C2 (en) 2011-06-10
NO20084318L (no) 2008-10-15
KR101059614B1 (ko) 2011-08-25
RS51450B (en) 2011-04-30
US8153807B2 (en) 2012-04-10
MY148079A (en) 2013-02-28
IL194810A0 (en) 2009-09-22
CA2646624C (en) 2013-08-06
AU2007244955B2 (en) 2011-12-08
WO2007127688A3 (en) 2007-12-21
IL194810A (en) 2012-12-31
BRPI0710467A2 (pt) 2011-08-16
SI2021336T1 (sl) 2010-11-30
CO6140034A2 (es) 2010-03-19
HK1126208A1 (en) 2009-08-28
KR20090034797A (ko) 2009-04-08
ZA200808687B (en) 2010-01-27
ES2345792T3 (es) 2010-10-01
PL2021336T3 (pl) 2010-11-30
EP2021336A2 (en) 2009-02-11
TNSN08417A1 (en) 2010-04-14
DE602007007473D1 (en) 2010-08-12
JP2009534468A (ja) 2009-09-24
CR10402A (es) 2009-07-13

Similar Documents

Publication Publication Date Title
CY1110753T1 (el) Αναστολεις της 11-βητα-υδροξυστεροειδους αφυδρογονασης i
CY1112466T1 (el) ΠΥΡΡΟΛΙΔΙΝΟΝΕΣ ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΜΕ ΠΙΠΕΡΙΔΙΝΥΛΙΟ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ 11-β-ΥΔΡΟΞΥΣΤΕΡΟΕΙΔΟΥΣ ΑΦΥΔΡΟΓΟΝΑΣΗΣ 1
DK2049475T3 (da) Cyclohexyl-substituerede pyrrolidinoner som inhibitorer af 11-beta-hydroxysteroid dehydrogenase1
DK2035379T3 (da) Inhibitorer af 11-beta-hydroxysteroiddehydrogenase 1
ATE472531T1 (de) Sulfonylverbindungen als hemmer von 11-beta- hydroxysteroiddehydrogenase-1
EA200870460A1 (ru) Производные циклогексилпиразол-лактама в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы 1
DK2021337T3 (da) Inhibitorer af 11-beta-hydroxysteroid-dehydrogenase-1
DK1807072T3 (da) Cycloalkyllactamderivater som inhibitorer af 11-beta-hydroxysteroid-dehydrogenase 1
CY1116064T1 (el) Συστασεις αναστολεα ddp iv
CY1112483T1 (el) Αγωνιστες gpcr πιπεριδινης
EA200870462A1 (ru) Производные бифениламидлактама в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы 1
ATE557024T1 (de) Piperidinverbindungen als gpcr-agonisten
CL2007002890A1 (es) Compuestos derivados de 2-piridincarboxamida, activador de glucosinasa; composicion farmaceutica; y uso del compuesto para el tratamiento de diabetes o la obesidad.
MX2009007180A (es) Agonistas del receptor acoplado a la proteina g de la piperidina.
NO20080010L (no) GPCR-agonister
CY1109696T1 (el) Υποκατεστημενα παραγωγα πυριδινυλιου και πυριμιδινυλιου ως διαμορφωτες του μεταβολισμου και η θεραπεια των σχετικων με αυτον διαταραχων
DE602007007614D1 (de) Substituierte pyrrolidinone als hemmer von 11-beta-hydroxysteroiddehydrogenase 1
GT200600046A (es) Terapia de combinacion
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
ATE442349T1 (de) Diacylglycerol-acyltransferase-hemmer
ATE557023T1 (de) Piperidinylverbindungen als gpcr-agonisten
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
ECSP077130A (es) Uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas en el tratamiento de náuseas y vómitos
EA200870515A1 (ru) Моноциклические гетероарильные соединения
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.